Financial Results : AME profit rises 26% to SAR 33.5M in 2023

AME profit rises 26% to SAR 33.5M in 2023

25/03/2024 Argaam Exclusive

View other reports

AME Company for Medical Supplies posted a net profit rise of 26% to SAR 33.5 million in 2023 from SAR 26.7 million in 2022.



Financials (M)

Item 2022 2023 Change‬
Revenues 193.17 223.32 15.6 %
Gross Income 90.28 98.75 9.4 %
Operating Income 29.98 36.48 21.7 %
Net Income 26.68 33.52 25.6 %
Average Shares 7.00 7.00 -
EPS (Riyals) 3.81 4.79 25.6 %

The company recorded a rise in the annual net revenue (net sales revenues) by SAR 30.15 million, mainly due to increased sales of medical supplies and medical equipment. This increase was backed by AME capturing a larger market share.



Current Half Annual Comparison (M)

Compared With The
Item H2 2022 H2 2023 Change‬
Revenues 84.82 102.98 21.4 %
Gross Income 41.42 43.06 4.0 %
Operating Income 12.72 12.47 (2.0 %)
Net Income 11.31 11.32 0.1 %
Average Shares 7.00 7.00 -
EPS (Riyals) 1.62 1.62 0.1 %

Shareholders’ equity, no minority interest, reached SAR 127.16 million as of Dec. 31, 2023, up from SAR 107.34 million a year earlier.

 

Historical Data

Period

Revenue

(SAR mln)

Net Profit

(SAR mln)

EPS

(SAR)

H1 2020

44.66

4.18

0.60

H2 2020

76.94

16.89

2.41

H1 2021

69.78

7.50

1.07

H2 2021

81.61

13.72

1.96

H1 2022

108.35

15.38

2.20

H2 2022

84.82

11.30

1.61

H1 2023

120.34

22.20

3.17

H2 2023

102.98

11.32

1.62

Kindly, you can view the full report by subscribing to the

The report contains the details of the financial statements, The most important financial indicators, Historical information, Charts, and Forecasts of experts.


Comments {{getCommentCount()}}

Be the first to comment

{{Comments.indexOf(comment)+1}}
{{comment.FollowersCount}}
{{comment.CommenterComments}}
loader Train
Sorry: the validity period has ended to comment on this news
Opinions expressed in the comments section do not reflect the views of Argaam. Abusive comments of any kind will be removed. Political or religious commentary will not be tolerated.